Ahead of its JPM20 presentation, Agios Pharmaceuticals (NASDAQ:AGIO) announces its key milestones and outlook for 2020. Highlights:
Tibsovo (ivosidenib) sales: $105M – 115M.
Receive CHMP opinion Europe on Tibsovo for relapsed/refractory AML with IDH1 mutation by year-end.
Complete enrollment in Phase 3 study, AGILE, evaluating the combination of Tibsovo and azacitidine in treatment-naïve IDH1-positive blood cancers by year-end.
File supplemental marketing application in U.S. by year-end for Tibsovo in previously-treated IDH1-positive cholangiocarcinoma.
Release topline data from ACTIVATE and ACTIVATE-T studies of mitapivat in adults with pyruvate kinase deficiency by year-end.
Achieve proof-of-concept for mitapivat in sickle cell disease by mid-year.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.